ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy by Marinelli, O et al.
  1 
ICOS-L as a Potential Therapeutic Target for Cancer 1 
Immunotherapy 2 
Marinelli Oliviero 1,*, Nabissi Massimo 1,*#, Morelli Maria Beatrice1, Amantini Consuelo2, Torquati Luciana3, Santoni 3 
Giorgio1,  4 
1) School of Pharmacy, University of Camerino, Camerino (MC), Italy 5 
2) School of Bioscience and Veterinary Medicine, University of Camerino, Camerino (MC), Italy 6 
3) Exeter University Medicine School, University of Exeter, Exeter, United Kingdom 7 
4) School of Human Movement and Nutrition Sciences, University of Queensland, Queensland, Australia 8 
        9 
       * Equally contribute 10 
#Corresponding author: Dr. Massimo Nabissi, School of Pharmacy, Dept. Experimental Medicine, via Madonna 11 
delle Carceri 9, 62032 Camerino (MC), Italy. e-mail: massimo.nabissi@unicam.it, phone:+390737403306, 12 
fax:+390737403325 13 
 14 
Graphical Abstract  15 
Abstract 16 
Background: The co-stimulatory B7 family members are cell-surface protein ligands, binding to receptors on lymphocytes 17 
to regulate immune responses. One of them is the inducible co-stimulatory molecule ligand (ICOS-L). This is expressed 18 
on professional antigen-presenting cells (APCs), including B cells, macrophages, and dendritic cells (DCs), but it can also 19 
be expressed by endothelial cells, lung epithelium and in tumour microenvironment cells. ICOS-L is important for 20 
memory and effector T cells during the specific humoral immune responses, but its role in cancer is not yet understood. 21 
Objective: To discuss the role of ICOS/ICOS-L in cancer, given importance of identifying selective targets for cancer 22 
treatment and knowing the mechanism of immune evasion by tumour 23 
Main findings: ICOS/ICOS-L signal has opposite effects on the T-cell response. ICOS-L is activated in several types of 24 
cancers to maintain immunosuppressive CD4+ T cell subsets, such as regulatory T cells (Rs). ICOS-L over-expression is 25 
associated with tumour progression and poor overall survival. In colon cancer, activation of this co-stimulatory signal is 26 
associated with improved survival suggesting a dualistic effect of the ICOS/ICOs-L signal pathway. Interestingly, 27 
following anti-cancer vaccine or anti-CTLA-4 treatment, ICOS+ T cells increased significantly in both the CD4+ and 28 
CD8+ population and the ratio Teff/Treg increased in tumour microenvironment. Thus suggesting a potential role of 29 
ICOS/ICOs-L in improving effectiveness of cancer therapy. 30 
 31 
Conclusion: ICOS/ICOS-L signal pathway has the potential to improve cancer treatment. However, future studies in other 32 
models are needed to understand whether  inhibition of ICOS expression or the blockage of its co-stimulation could be a 33 
potential therapeutic target or adjuvant treatment for immunotherapy. 34 
 35 
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1.1 ICOS-L, a member of co-stimulatory B7 family. 38 
The co-stimulatory B7 family members are cell-surface protein ligands, binding to receptors expressed on lymphocytes 39 
and involved in regulating immune responses. This system not only provides positive signals to stimulate T-cell 40 
activation, but also it delivers negative signals to inhibit T-cell responses. The inducible co-stimulatory molecule ligand 41 
(ICOS-L), also known as B7RP-1, B7-H2, LICOS, GL50, B7h and CD275, is a member of B7 family. It is expressed on 42 
professional antigen-presenting cells (APCs), including B cells, macrophages and dendritic cells (DCs), but also in  certain 43 
endothelial cells and lung epithelium [1-3]. Despite limited evidence, ICOS-L is known to act as a co-stimulatory signal 44 
for T-cell proliferation and cytokines secretion and to induce B-cell proliferation and differentiation into plasma cells. 45 
ICOS-L could also play an important role in mediating local tissue responses to inflammatory conditions and in 46 
modulating the secondary immune response by co-stimulating memory T-cell function [2, 3]. 47 
1.1.1. ICOS-L: gene, transcripts and proteins. 48 
 The gene encoding the inducible co-stimulator ligand (ICOS-L), is located in the 21q22.3, is 24,477 bases in 49 
length and contains 10 exons [4]. At transcriptional level, four transcript variants (Var) have been cloned. Vara (the 50 
canonical form) represents the longest transcript (3320 nts) and encodes the isoform a, Varb (1188 nt) uses an alternative 51 
3' terminal exon and it thus differs in the 3' coding region and 3' UTR, compared to Vara. Varc (2969 nt) lacks an alternate 52 
in-frame exon in the 5' coding region, compared to Vara, resulting in an isoform c that is shorter than isoform a. Vard 53 
(3168 nt) uses an alternate splice site in the 5' region, resulting in translation initiation at a downstream in-frame start 54 
codon, compared to Vara. The encoded isoform d is shorter at the N-terminus, compared to isoform a (Fig.1, 55 
Supplementary 1). Isoform a is widely expressed (brain, heart, kidney, liver, lung, pancreas, placenta, skeletal muscle, 56 
bone marrow, colon, ovary, prostate, testis, lymph nodes, leukocytes, spleen, thymus and tonsil), while isoform b is 57 
detected only in lymph nodes, leukocytes, spleen and it is expressed on activated monocytes and dendritic cells [5]. Tissue 58 
and organ expression of Varc and Vard are yet to be studied. 59 
1.2 Immunological role of ICOS-L 60 
 ICOS-L specifically binds the T-cell inducible co-stimulatory molecule (ICOS), also named CD278 [3], which 61 
is expressed at high levels in germinal center T cells or TFH (follicular helper) cells. Activation of ICOS receptor induces 62 
recruitment of class IA phosphatidylinositol 3-kinase (PI3K), a signalling molecule that leads to the production of 63 
membrane-bound phosphatidylinositol 3,4,5-trisphosphate (PIP3). This culminates in the activation of Akt, a kinase that 64 
promotes cellular proliferation and survival. ICOS activation also recruits the p50α and p85α regulatory subunits and 65 
p110δ catalytic subunit of PI3K. In vivo and in vitro experiments indicate that ICOS/ICOS-L pathway activation 66 
contributes to the production of cytokines, such as IL-5, IL-4,IL-10 and IL-13. ICOS/ICOS-L co-stimulatory signal is 67 
important for memory and T helper cell effector functions. This is particularly important for T helper-2 differentiation 68 
and antibodies response during the specific humoral immune responses against pathogens such as bacteria, parasites, and 69 
viruses [1,2]. Moreover, ICOS-L seem to alternatively promote or repress T helper-1 responses under different infection 70 
conditions and these divergent phenotypes may in part be explained by ICOS-dependent regulatory T cells (Tregs) 71 
induction (Fig. 2). Thus, the ability of ICOS-L to influence Tregs induction points to a complex role in regulating CD4+ 72 
T cell differentiation, and  suggests that ICOS-L signalling may be mutually important in preventing immune-mediated 73 
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1.3 ICOS-L in tumour infiltrate lymphocytes 78 
 Malignant cells may adopt several mechanisms to interfere with the effector immune response or with regulatory 79 
cells in tumour microenvironment, in order to escape from immune surveillance. Regulatory T cells (Tregs) constitute 80 
5% to 10% of all peripheral CD4+ T cells and play an important role in maintaining tolerance to both auto-immune and 81 
cancer cells. Starting from the identification of Forkhead box protein 3 (Foxp3) as a critical transcriptional factor for 82 
Tregs, Foxp3+CD4+ T cells have been regarded as Tregs with immunosuppressive functions and divided in three 83 
subpopulations: effector Tregs (eTregs), naive Tregs, and non-Tregs [6]. Tregs, like other T cells, respond to TCR 84 
stimulation. They also express co-stimulatory receptors, such as CTLA-4, PD-1, ICOS and CD28 that further promote 85 
their activation, proliferation and survival(ref). A large body of evidence confirms that activation of ICOS/ICOS-L 86 
pathway is involved in maintenance of this subtype of T cells in tumour microenvironment, which usually is associated 87 
with a poor prognosis of patient [6].  88 
 89 
1.3.1. ICOS-L in cancer 90 
 ICOS/ICOS-L pathway was reportedly activated in melanoma [7], myeloma [8,9], breast [10], ovarian [11], 91 
gastric [6], liver [12] and colorectal cancers [13]. Furthermore, ICOS-L was also found in classical Hodking lymphoma 92 
[14], B lymphoma [2], leukemia [15], glioblastoma [16] and rhabdomyosarcoma [17], but its role in these cancers is yet 93 
to be completely elucidated. In tumour microenvironment, Treg cells contribute to tumour growth by inhibiting tumour-94 
specific immunity through not yet characterized mechanisms. It is hypothesised that this mechanism may involve FAS-95 
L, CD39/Adenosine, perforins, CTLA-4, or PD-1 and the generation of high levels of IL-10, which mediate a suppressive 96 
capability, especially against dendritic cell functions. Finally, it was demonstrated that ICOS/ICOS-L pathway could 97 
modulate the efficacy of therapy in patients with prostate cancer [18], pancreatic cancer [19], bladder cancer [20], multiple 98 
myeloma [21] and melanoma [22,23].  99 
 100 
1.3.2 ICOS-L in melanoma 101 
 Melanoma tumour biopsies analysis showed an estimated  25% of the CD4+ T cells found were Foxp3+, more 102 
than 3 times the abundance found in the peripheral blood of the same patients (7%).This indicates that ICOS-L expressed 103 
by melanoma cells could co-stimulate Tregs to induce high levels of Foxp3, CD25, ICOS and also production of IL-10. 104 
This evidence suggest that tumour cells may act themselves as direct APC, since they can express HLA class II and 105 
provide self-antigen presentation and co-stimulation through ICOS-L, allowing a tumour self-tolerance [7].  106 
 107 
1.3.3. ICOS-L in haematological tumors 108 
 In several haematological malignancies, ICOS-L was expressed in cancer cells. Malignant Hodgkin Reed 109 
Sternberg cells derived from a germinal center B cells over-expressed different surface molecules, including CD70, 110 
CD80/CD86, CD30, CD40, OX40-L/CD252, and ICOS-L. Their respective receptors were often present on typical 111 
Hocking lymphoma microenvironment immune cells and was considered to be up-regulated on activated T Helper cells 112 
(ref). Evidence suggests that malignant tumours were capable of sequestering a substantial number of activated functional 113 
T cells, contributing to a profound systemic immune deficit in advanced disease [14]. Additionally, it was shown that 114 
leukemic cells, obtained from patients with acute myeloid leukemia, express ICOS-L and this it was associated with a 115 
poor prognosis(ref). Thus suggesting that expression of ICOS-L in leukemic cells might contribute to their proliferation 116 
by helping them to evade antitumor immune responses [15]. Although ICOS-L expression has been evaluated on B 117 
lymphoma tissues, its biological functions in regulating anticancer immune response is not completely understood [2]. 118 
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Immunohistochemical staining showed that ICOS-L was expressed in thyroid B-cell lymphoma but not in thyroid 119 
adenoma tissue or healthy thyroid tissue, suggesting that ICOS-L molecules may be involved in the development of 120 
malignant B lymphoma [2]. In an in vitro model of myeloma, tumour cells express ICOS-L [8,9] which directly induces 121 
not only Tregs expansion but also Treg cells generation in a contact-dependent manner and in absence of APC cells. The 122 
induction of Treg cells mediated by cell-to-cell contact with the ICOS/ICOS-L system supports the hypothesis that this 123 
pathway may play a central role in the immune suppression response [8].  124 
 125 
1.3.4 ICOS-L in ovarian and breast cancer 126 
 While previously described evidence indicated ICOS-L expression in tumour cells, recent investigations in 127 
ovarian cancer and breast cancer are in contrast with this theory. In ovarian and breast cancer, ICOS-L was not expressed 128 
in cancer cells indicating that Tregs expansion was activated by other cells expressing ICOS [10,11]. In ovarian cancer 129 
many Foxp3+ Treg cells were found to infiltrate the tumour microenvironment, a phenomenon that strongly predicts 130 
disease progression. These Tregs constitutively expressed ICOS and were frequently detected in the tumour of patients 131 
with epithelial ovarian cancer. Survival, proliferation and functions of ICOS+Foxp3+Treg cells was strictly dependent to 132 
the presence of tumour-infiltrating plasmacytoid dendritic cells (pDCs) [11]. Human DCs consist of two subsets, myeloid 133 
dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs). The first derive from TLR2-6, 8 and induce T helper 1 134 
effector cells, while pDCs mature from TLR7 and 9 and have been reported to exist in most human solid tumours. pDCs 135 
are associated with induction and maintenance of immunosuppressive conditions by the secretion of indoleamine 2,3-136 
dioxygenase, IL-3, expression of ICOS-L, CD40-L and through Treg cells activation. There is substantial evidence 137 
suggesting that pDCs have a specialized role in the induction of peripheral tolerance by inducing IL-10-production 138 
through Tregs-ICOS-L/ICOS signalling [6,24]. In summary, in epithelial ovarian cancer the ICOS/ICOS-L pathway 139 
activation involveed a tumor-infiltrating pDCs that express high levels of ICOS-L, while cancer cells did not express 140 
significant levels of this protein. This evidence supports the hypothesis that tumor-infiltrating pDCs were directly 141 
involved in creating an immunosuppressive tumour microenvironment through the expansion of the ICOS+Foxp3+ Treg 142 
cell subset [11]. 143 
 Likewise, infiltration of pDS indirectly induced by ICOS was associated with poor prognosis of breast cancer 144 
patients [10]. While ICOS-L was not expressed in neither primary breast tumour cells or in breast tumour cell lines,  ICOS 145 
engagement was described as a major contributing pathway to ICOS+Tregs local accumulation. Tumour-associated 146 
ICOS+Tregs directly interacted with pDCs in situ, as confirmed by immunohistochemistry on primary breast tumour 147 
frozen sections. Upstream of this cascade, CCL22 was produced by tumor cells to recruit CCR4+Treg cells from the 148 
bloodstream to breast tumour microenvironment. This resulted in CCR4+Treg cells local expansion through ICOS/ICOS-149 
L interaction with pDC in breast tumour environment [10]. 150 
 151 
1.3.5. ICOS-L in gastric and liver cancers 152 
 In gastric cancer, a high number of ICOS+ cells were found in gastric tissue of late-stage gastric cancer patients. 153 
In this patients, the expression level of ICOS-L was high in pDCs while high ICOS expression in Foxp3+ infiltrating T 154 
lymphocyte was associated with a poor prognosis. Immunohistochemistry results showed a coexistence of ICOS+Foxp3+ 155 
cells and pDCs in gastric cancer tissues suggesting some functional relationship between these cells, as seen in other 156 
tumour types [6]. Additionally, this ICOS/ICOS-L pathway was not only involved in regulating the Treg cell subset but 157 
also  other types of inhibitory T cells potentially involved in local immunosuppression. Among these, T regulatory type 158 
1 cells (Treg1), initially considered important in promoting and maintaining tolerance in autoimmunity, allergy and 159 
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transplantation, also demonstrated to be involved in promoting tumour escape from immune surveillance [12]. In patients 160 
with primary and secondary liver cancer, tumour infiltrating Treg1 cells contributed to local immune suppression via 161 
ICOS/ICOS- L signalling and ICOS-L+pDCs stimulated IL-10 production in the tumour microenvironment [12].  162 
 163 
1.3.6. ICOS-L in others solid cancers. 164 
 ICOS-L was found expressed in human glioma cells, both in vitro and in vivo but not in normal central nervous 165 
system tissues adjacent to the neoplastic cells. Whether ICOS-L plays a role in supporting theses malignancy is yet to be 166 
investigated [16]. In rhabdomyosarcoma (RMS), the most common paediatric soft tissue malignancy, ICOS-L was 167 
expressed in FLOH1, RH41, RD6, and TE671 RMS cell lines and its expression levels marginally increased in presence 168 
of TNFα [17]. Even if the involvement of ICOS/ICOS-L pathway supported cancer progression and worsen prognosis in 169 
several cancer models, in colorectal cancer the expression of ICOS was associated with a good prognosis [13]. Although 170 
limited data is available on ICOS-L expression in colorectal cancer,  ICOS is known to be mainly expressed on CD4+T 171 
cells in patients’ tumour tissues or peripheral blood cells [13]. Compared to ICOS-T cells, ICOS+T cells produce more 172 
INFγ and less IL-4 and show up-regulated expression of transcriptional factor of Th1 cells (T-bet). This suggests that 173 
ICOS promotes Th1 effector response in patients with colon cancer. It is known that Th1 cells inhibit tumour cell invasion 174 
and metastasis by communicating with tumour-associated myeloid cells (i.e. tumour-associated macrophages and 175 
myeloid-derived suppressor cells) contributing to an improvement of survival. Studies showed a significant correlation 176 
between high ICOS expression and good prognosis, in relation to tumour size, Carcinoembryonic antigen (CEA) levels, 177 
tumor staging, lymphatic metastasis and distant metastasis (TNM classifications). Furthermore, ICOS expression was 178 
correlated with the expression of checkpoint inhibitors CTLA-4 and PD-1 on T cells, indicating that ICOS could also be 179 
a useful marker for a selection of anti-CTLA-4 or PD-1 therapy in colorectal cancer [13]. 180 
 181 
1.4 ICOS/ICOS-L pathway in cancer immunotherapy 182 
 The opposite effects of ICOS/ICOS-L pathway on the T-cell response may explain the lack of antitumor efficacy 183 
of ICOS-L blockade in mono-therapy [25]. Instead, studies blocking the ICOS/ICOS-L pathway in combination with 184 
other therapy showed different results. For example, therapy with GM-CSF-modified cancer cell vaccine combined with 185 
anti-ICOS monoclonal antibody induced more powerful anti-tumour immunity [18]. Indeed, Mo et al. demonstrated in 186 
murine models of prostate cancer how tumour-infiltrated T lymphocyte increased after treatment with GM-CSF-modified 187 
cancer cell vaccine and how combination therapy induced higher infiltration compared with vaccine alone. Furthermore, 188 
ICOS+Foxp3+T cells infiltration into tumour tissues were higher after vaccine therapy, while the proportion of these cells 189 
decrease in combination treatmenr compared with control condition. Although the vaccine induced an efficient antitumor 190 
immunity inhibiting tumour growth, it also induced an increase of Tregs tumour infiltration that could challenge the 191 
effectiveness of this therapy. In this case, combination with ICOS blocking could deplete infiltrated Tregs with the 192 
possibility to enhance the vaccine-induced immunity [18].  193 
 194 
Further supporting this evidence, treatment of pancreatic cancer targeting mesothelin (MSLN), a potential immune-195 
therapeutic target, showed similar results. MSLN-virus-like particles (mMSLN-VLPs) immunization was able to break 196 
tolerance to intrinsic MSLN, resulting in reduced frequency of CD4+Foxp3+ICOS-Treg cells and stimulation of cytotoxic 197 
CD8+ T cells antitumor activity. However, because mMSLN-VLP induces IL-6 production, increasing ICOS-L expression 198 
on pDC-like cells and proliferation of immunosuppressive CD4+Foxp3+ICOS+Treg cells, combination therapies with 199 
ICOS blocking remain necessary [19]. In an in vitro model of multiple myeloma, lenalidomide pre-treatment of MM cell 200 
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lines reduced Treg generation and the Treg/TEff ratio, probably due to a reduced ICOS-L gene transcription. Combined 201 
treatment with lenalidomide and dexamethasone significantly reduced both Treg induction and the Treg/TEff cell ratio 202 
[21]. Additionally, depletion of Tregs in conjunction with ICOS agonist could remove the potential immunosuppressive 203 
effects of ICOS signalling and allow ICOS agonist to act solely in promoting activity of CD4+ Teff.  In fact, ICOS is 204 
highly expressed in tumor Tregs, and thus a single ICOS agonist with strong Fc engagement may be sufficient to induce 205 
a simultaneous ADCC-mediated depletion of Tregs and agonist-based enhancement of anti-tumour responses [25].  206 
 207 
Nevertheless, blocking of ICOS/ICOS-L system not always demonstrated to be good strategy. Results in in vivo models 208 
of prostate, melanoma [22] and bladder cancer [20], showed anti-CTLA-4 therapy leaded to an increase in the frequency 209 
of CD4+ICOS+ and CD8+ICOS+ T cells producing IL-2 and IFN- Here, ICOS seemed to play an important role in the 210 
activation/development of functional antitumor CD8 T cells [23]. In mouse syngeneic tumours, ICOS was found highly 211 
expressed by Tregs, but it was also found up-regulated across CD8+ and CD4+ effector populations, suggesting that ICOS 212 
expression was associated with opposite functions. According to this evidence, ICOS/ICOS-L pathway could be another 213 
therapeutic target and it may have implications in the development of novel combined cancer immunotherapy strategies 214 
[22,23]. Indeed, in murine models of prostate cancer, CTLA-4 blockade enhanced activation of tumour-reactive T cells 215 
with concomitant up-regulation of ICOS. In this context, IVAX (vaccine of ICOSL-positive tumour cells) triggered the 216 
ICOS pathway, leading to a higher density of Teff cells inside the tumour, as indicated by an increase in the Teff/Treg 217 
cell ratio [22]. Likewise, after anti–CTLA-4 treatment ICOS+ T cells increased significantly in both the CD4+ and CD8+ 218 
populations. In this case, anti–CTLA-4 therapy increased a population of Foxp3- cells and then stimulated an expansion 219 
of ICOS+ T effector cells over Treg cells. This results suggest that ICOS+ T cells may represent a population of T effector 220 
cells that play an important role in antitumor immune responses induced by anti–CTLA-4 therapy. Further, ICOS+ T cells 221 
produced Th1 cytokine IFN- and cytokine IL-2 necessary for effective antitumor responses, suggesting that ICOS+ T 222 
cells might play a functional role in improving the effectiveness of combinatorial immunotherapy. In a recent clinical 223 
trial, treatment of patients with bladder cancer were with a blocking anti-CTLA-4 mAb resulted in increased percentage 224 
of CD4+T cells in peripheral blood and tumour tissues, thus potential higher levels of ICOS. Upon re-stimulation, 225 
ICOS+CD4+ T cells produced greater levels of IFN- compared to ICOS-CD4+ T cells, suggesting that T cells with higher 226 
levels of ICOS, have elevated effector functions in antitumor activity, as seen in melanoma models [20]. 227 
 228 
2. CONCLUSION 229 
The pathway ICOS/ICOS-L is involved in several processes in cancer, ranging from support of tumour growth but, at the 230 
same time, improvement of immune-stimulating therapy efficacy. Data suggest that inhibition of ICOS/ICOS-L system 231 
alone may not particularly effective in treatment of cancer because this pathway showed opposing effects in regulating 232 
T-cell response. The importance of ICOS/ICOS-L blockade was attributable to its role as adjuvant in combined cancer 233 
immunotherapy strategies. ICOS expression was positively correlated with the expression of other important immune 234 
checkpoints (CTLA-4 and PD-1 on T cells) in colon cancer patients, with antibodies anti-CTLA-4 and anti PD-1 currently 235 
being used for the treatment of several types of cancer. This suggest that ICOS could be a marker in therapy selection, 236 
with effectiveness depending on CTLA-4 or PD-1 expression correlated with ICOS expression.  While increasing of 237 
Tregs in tumour microenvironment could reduce vaccine efficacy, a combination with anti-ICOS antibody might be a 238 
more effective therapy. This could increase immune response, as it would reduce the population of tumour infiltrated 239 
Tregs. In summary, ICOS/ICOS-L pathway could be considered as a novel immune target and its role should be 240 
investigated in other cancers, taking into account that this pathway shows a dualistic behaviour. 241 
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Figure 1. Alignment analysis of ICOS-L transcripts.  NM_015259.5  (Vara, 3320 nt), NM_001283050.1 (Varb, 1188 nt), 249 
NM_001283051.1 (Varc, 2969 nt), NM_001283052.1 (Vard, 3168 nt).  The analysis was performed by Clustal Omega 250 
software. * (Asterisk) indicates positions that have a single, fully conserved residue. 251 
 252 
Figure 2. Sequence alignment analysis of ICOS-L protein variants. Vara (NP_056074.1, 302 aa), Varb 253 
(NP_001269979.1, 309 aa), Varc (NP_001269980.1, 185 aa), Vard (NP_001269981.1, 217 aa). * (asterisk) indicates 254 
positions which have a single, fully conserved residue. : (colon) indicates conservation between groups of strongly similar 255 
properties..(period) indicates conservation between groups of weakly similar properties. In Bold: trans-membrane 256 
domain, Clear: cytoplasmatic domain, Underline and clear: extracellular domain. Alignment analysis was performed by 257 
Clustar Omega software. 258 
 259 
Figure 3. ICOS-ICOS-L pathways. ICOS-L is a member of B7 family expressed on professional antigen-presenting 260 
cells (APCs) and it binds ICOS receptor expressed on T cells. Activation of ICOS receptor induces the recruitment PI3K, 261 
a signalling molecule that leads to the activation of Akt, a kinase that promote cellular proliferation and survival. 262 
ICOS/ICOS-L pathway activation contributes to the production of cytokines, such as IL-5, IL-4, IL-13 and IL-10. It is 263 
suggested that ICOS/ICOS-L co-stimulatory signal is very important for memory and T helper cell effector functions but, 264 
ICOS is seemingly capable of alternatively promoting or repressing T helper-1 responses by ICOS-dependent regulatory 265 
T cells (Tregs) induction. 266 
 267 
Tab. 1 Differential role of ICOS-L/ICOS activation in different tumours. ICOS/ICOS-L pathway is activated in different 268 
types of cancer and it plays a central role in immune suppression. ICOS-L is present in tumour microenvironment because 269 
it is expressed by cancer cells or tumour-infiltrating plasmacytoid dendritic cells (pDCs). 270 
  271 
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